NCT01460511View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of E004 in Children With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

July 31, 2012

Conditions
Asthma
Interventions
DRUG

E004 (Epinephrine Inhalation Aerosol) HFA-MDI

E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID

DRUG

Placebo-HFA

Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID

Trial Locations (8)

29406

Amphastar Site 7, North Charleston

78229

Amphastar Site 6, San Antonio

79903

Amphastar Site 3, El Paso

92626

Amphastar Site 5, Costa Mesa

92868

Amphastar Site 8, Orange

95207

Amphastar Site 4, Stockton

97202

Amphastar Site 1, Portland

97504

Amphastar Site 2, Medford

Sponsors
All Listed Sponsors
lead

Amphastar Pharmaceuticals, Inc.

INDUSTRY